AIM Biotech Launches Organ-on-a-Chip Contract Research Service
March 1, 2021 - Singapore & Boston, MA - AIM Biotech has launched a contract research service, which uses its organ-on-a-chip technology to accelerate and improve drug discovery and development. AIM's 3D microfluidic organ-on-a-chip platform more accurately mimics the human microenvironment than conventional assays. As a result, drug discovery organizations can generate more predictive data and better inform their decisions ahead of clinical trials.
To view the full announcement, including downloadable images, bios, and more, click here.
- Drug discovery companies can free up resources to take advantage of AIM's organ-on-a-chip technology at a joint service laboratory with the Agency for Science, Technology and Research (A*STAR)'s Institute of Molecular and Cell Biology (IMCB) in Singapore.
- The AIM organ-on-a-chip platform generates more predictive human data for drug discovery & development.
- Validated applications include cancer and immunotherapy, vascular functions, neurobiology and various aspects of cell biology.
Click image above to view full announcement.
AIM gives researchers 3D human biology-on-a-chip to revolutionize their preclinical drug discovery and molecular research. At its core is the AIM Chip, a specialized 3D microfluidics device that makes it easy to generate relevant human data from disease-specific assays. Researchers are able to create their own assays or apply validated protocols, which include angiogenesis, vasculogenesis, metastasis, immuno-oncology, and 3D culture of tumor samples. AIM Biotech is located in Singapore and Boston, MA.
Media & Investors
Source: AIM Biotech
Distributed by: Reportable, Inc.